Clariane SEFRA:KO2 +1.50%60 ROA % is 0.85% as of Dec. 2025, which is 70% above its 10-year median of 0.50. GuruFocus rates FRA:KO2 with a GF Score™ of 60/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Clariane SE ranks worse than 63.25% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Clariane SE's annualizedNet Income for the quarter that ended in Dec. 2025 was €120 Mil.
Clariane SE's average Total Assets over the quarter that ended in Dec. 2025 was €14,109 Mil. Therefore, Clariane SE's annualized ROA % for the quarter that ended in Dec. 2025 was 0.85%.
The historical rank and industry rank for Clariane SE's ROA % or its related term are showing as below:
FRA:KO2'
s ROA % Range Over the Past 10 Years
Min: -0.71 Med: 0.5 Max: 2.4
Current: 0.01
During the past 13 years, Clariane SE's highest ROA % was 2.40%. The lowest was -0.71%. And the median was 0.50%.
FRA:KO2's ROA % is ranked worse than 63.25% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 1.77
vs FRA:KO2: 0.01
Clariane SE (FRA:KO2) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Clariane SE ROA % Related Terms
Clariane SE ROA % Historical Data
* Premium members only.
The historical data trend for Clariane SE's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Clariane SE's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's ROA % distribution charts can be found below:
* The bar in red indicates where Clariane SE's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Clariane SE (FRA:KO2) has a ROA % of 0.85% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Clariane SE and its competitors. This is 70% above median its historical median of 0.50. According to the industry distribution chart, Clariane SE ranks #432 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 63.3%.
Is Clariane SE's ROA % too high?
Clariane SE's current ROA % of 0.85% is 70% above median its 10-year median of 0.50. The Healthcare Providers & Services industry median ROA % is 1.77. Clariane SE's value of 0.85% is 52% below this industry median. Based on the distribution chart, Clariane SE ranks #432 out of 683 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Clariane SE has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's ROA % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #432 out of 683 companies for ROA %. This places Clariane SE in the lower half of its industry. The industry median ROA % is 1.77. Clariane SE's value of 0.85% is 52% below this benchmark. While the company's 10-year median is 0.50 vs. the industry median of 1.77, Clariane SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.77, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current ROA % of 0.85% is 52% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Clariane SE and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current ROA % is 0.85%, which is 70% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (FRA:KO2) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.20 — trading 70.1% above its estimated fair value. The current ROA % is 0.85%, which is 70% above median its 10-year median of 0.50 and 52% below the Healthcare Providers & Services industry median of 1.77. Clariane SE's overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Clariane SE (FRA:KO2), the current ROA % is 0.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (FRA:KO2) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €4.20 is trading 70.1% above its estimated GF Value™ of €2.47.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for FRA:KO2:
ROA %: 0.85% (70% above median its 10-year median of 0.50)
GF Value™: €2.47 vs. price of €4.20 (70.1% above fair value)
Industry Position: 52% below the Healthcare Providers & Services median (#432 of 683)
No single metric tells the full story. See the FRA:KO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
60GF Score
Get the complete analysis for FRA:KO2
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KO2 has been successfully added to your 
